Drug-induced hypersensitivity to artemisinin-based therapies for malaria

Tamara Nordmann; Steffen Borrmann; Michael Ramharter

doi:10.1016/j.pt.2021.08.011

Drug-induced hypersensitivity to artemisinin-based therapies for malaria

Standard

Drug-induced hypersensitivity to artemisinin-based therapies for malaria. / Nordmann, Tamara; Borrmann, Steffen; Ramharter, Michael.

in: TRENDS PARASITOL, Jahrgang 38, Nr. 2, 02.2022, S. 136-146.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Review › Forschung

Harvard

Nordmann, T, Borrmann, S & Ramharter, M 2022, 'Drug-induced hypersensitivity to artemisinin-based therapies for malaria', TRENDS PARASITOL, Jg. 38, Nr. 2, S. 136-146. https://doi.org/10.1016/j.pt.2021.08.011

APA

Nordmann, T., Borrmann, S., & Ramharter, M. (2022). Drug-induced hypersensitivity to artemisinin-based therapies for malaria. TRENDS PARASITOL, 38(2), 136-146. https://doi.org/10.1016/j.pt.2021.08.011

Vancouver

Nordmann T, Borrmann S, Ramharter M. Drug-induced hypersensitivity to artemisinin-based therapies for malaria. TRENDS PARASITOL. 2022 Feb;38(2):136-146. https://doi.org/10.1016/j.pt.2021.08.011

Bibtex

@article{8863cde264d54f22950861c98dc4ef35,

title = "Drug-induced hypersensitivity to artemisinin-based therapies for malaria",

abstract = "In the early 2000s, artemisinin-based combination therapy (ACT) was introduced as first-line treatment for uncomplicated Plasmodium falciparum malaria in virtually all endemic countries. However, despite the well-known excellent tolerability of ACTs, hypersensitivity to artemisinin derivatives remains a repeatedly documented adverse drug reaction of still unknown frequency. The clinical features of an artemisinin-induced hypersensitivity reaction range from mild to life-threatening severity, and a significant number of cases may pass unnoticed. In this review, we discuss the medical importance of hypersensitivity to artemisinin derivatives and we review data on the presumed frequency and its potential underlying mechanisms. Furthermore, we advocate to make alternative non-artemisinin-based drugs available for patients who do not tolerate artemisinin derivatives and to continue investing in the development of novel non-artemisinin-based combination regimens.",

keywords = "Antimalarials/adverse effects, Artemisinins/adverse effects, Drug Therapy, Combination, Humans, Hypersensitivity, Malaria/drug therapy, Malaria, Falciparum/drug therapy, Plasmodium falciparum",

author = "Tamara Nordmann and Steffen Borrmann and Michael Ramharter",

year = "2022",

month = feb,

doi = "10.1016/j.pt.2021.08.011",

language = "English",

volume = "38",

pages = "136--146",

journal = "TRENDS PARASITOL",

issn = "1471-4922",

publisher = "Elsevier Limited",

number = "2",

}

RIS

TY - JOUR

T1 - Drug-induced hypersensitivity to artemisinin-based therapies for malaria

AU - Nordmann, Tamara

AU - Borrmann, Steffen

AU - Ramharter, Michael

PY - 2022/2

Y1 - 2022/2

N2 - In the early 2000s, artemisinin-based combination therapy (ACT) was introduced as first-line treatment for uncomplicated Plasmodium falciparum malaria in virtually all endemic countries. However, despite the well-known excellent tolerability of ACTs, hypersensitivity to artemisinin derivatives remains a repeatedly documented adverse drug reaction of still unknown frequency. The clinical features of an artemisinin-induced hypersensitivity reaction range from mild to life-threatening severity, and a significant number of cases may pass unnoticed. In this review, we discuss the medical importance of hypersensitivity to artemisinin derivatives and we review data on the presumed frequency and its potential underlying mechanisms. Furthermore, we advocate to make alternative non-artemisinin-based drugs available for patients who do not tolerate artemisinin derivatives and to continue investing in the development of novel non-artemisinin-based combination regimens.

AB - In the early 2000s, artemisinin-based combination therapy (ACT) was introduced as first-line treatment for uncomplicated Plasmodium falciparum malaria in virtually all endemic countries. However, despite the well-known excellent tolerability of ACTs, hypersensitivity to artemisinin derivatives remains a repeatedly documented adverse drug reaction of still unknown frequency. The clinical features of an artemisinin-induced hypersensitivity reaction range from mild to life-threatening severity, and a significant number of cases may pass unnoticed. In this review, we discuss the medical importance of hypersensitivity to artemisinin derivatives and we review data on the presumed frequency and its potential underlying mechanisms. Furthermore, we advocate to make alternative non-artemisinin-based drugs available for patients who do not tolerate artemisinin derivatives and to continue investing in the development of novel non-artemisinin-based combination regimens.

KW - Antimalarials/adverse effects

KW - Artemisinins/adverse effects

KW - Drug Therapy, Combination

KW - Humans

KW - Hypersensitivity

KW - Malaria/drug therapy

KW - Malaria, Falciparum/drug therapy

KW - Plasmodium falciparum

U2 - 10.1016/j.pt.2021.08.011

DO - 10.1016/j.pt.2021.08.011

M3 - SCORING: Review article

C2 - 34561157

VL - 38

SP - 136

EP - 146

JO - TRENDS PARASITOL

JF - TRENDS PARASITOL

SN - 1471-4922

IS - 2

ER -